Aliceblue ANT
Aliceblue ANTInstall and trade smarter everywhere
Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd

NSE: SYNCOMF | BSE: 524470
19.46+0.20 (1.04%)
Trade now

    Performance

    Historical price movement and trading activity

    Trading Data

    Today's High

    20.1

    Today's Low

    18.51

    Open

    18.98

    Previous Close

    19.46

    Volume

    9148018

    Total Traded Value High

    177053167.01

    Overview

    Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE / BSE

    Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995. During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%. During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt. The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003. In 2007, the Company launched a new division 'Cratus Life Care' to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008. In 2023-24, Company has expanded the business by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum.

    Fundamentals

    Financial strength and ownership structure

    Valuation & Ratios

    Market Capitalisation

    ₹1,546.30

    Price to Book (PB)

    4.52

    Price to Earnings (PE)

    31.04

    Return on Equity (ROE)

    15.68%

    Earnings Per Share (EPS)

    0.53

    Dividend Yield

    0.00%

    Financial Performance

    63.84
    65.14
    74.57
    87.26
    102.31
    127.53
    148.88
    116.90
    121.72
    115.14
    135.41
    125.53
    Sep
    '23
    Dec
    '23
    Mar
    '24
    Jun
    '24
    Sep
    '24
    Dec
    '24
    Mar
    '25
    Jun
    '25
    Sep
    '25
    Dec
    '25
    Mar
    '26
    Jun
    '26

    Shareholding Pattern

    50.57%
    50.57%
    50.57%
    50.57%
    Sep
    '25
    Dec
    '25
    Mar
    '26
    Jun
    '26

    Technicals

    Price-based indicators and levels

    Indicators

    IndicatorValueSignal
    Relative Strength Index (RSI)+60.56Neutral
    MACD+1.43Bullish

    Support and Resistance Levels

    R321.23
    R220.75
    R120.01
    S118.79
    S218.31
    S317.57

    Moving Averages

    PeriodSMAEMA
    20D Moving Average18.4618.62
    50D Moving Average15.6216.63
    200D Moving Average14.1715.18

    News

    Syncom Formulations announces management changes, including new directors and CFO, pending approval

    11 Aug 2026

    Syncom Formulations (India) Limited announced changes to its board and senior management, effective August 11, 2026. The company said Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda resigned from their respective positions as Whole-time Director and Managing Director, while Rahul Vijay Bankda resigned as Chief Financial Officer. Subsequently, Rinki Ankit Bankda was appointed as Additional Director and Whole Time Director, Rahul Vijay Bankda as Additional Director and Managing Director, and Ankur Vijay Bankda as Chief Financial Officer, all subject to shareholder approval at the upcoming Annual General Meeting. Additionally, Smt. Ruchi Jindal was reappointed as Woman Independent Director, effective June 29, 2027, also pending shareholder approval.

    Syncom Formulations sets record date for dividend of Rs. 0.10 per equity share

    11 Aug 2026

    Syncom Formulations (India) Limited has fixed Wednesday, September 23, 2026, as the record date for determining entitlement to a dividend of Rs. 0.10 per equity share, representing 10% for the financial year ended March 31, 2026, subject to shareholder approval at the company’s 38th Annual General Meeting to be held on Wednesday, September 30, 2026, at 2:00 P.M. via video conferencing or other audio-visual means.

    SYNCOM Formulations to review financial results and potential dividend at August meeting

    6 Aug 2026

    SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.

    SYNCOM Formulations to review financial results and potential dividend at August meeting

    6 Aug 2026

    SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.

    Syncom Formulations (India) schedules board meeting

    14 May 2026

    On 22 May 2026

    Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 22 May 2026.

    Insider Activity

    Kedarmal Shankarlal BankdaPromoter & Director
    Acquired
    2731470
    Shares Worth
    ₹0
    Reported On16 Jun 2023
    ModeOff Market
    Asha BankdaPromoter Group
    Acquired
    13500000
    Shares Worth
    ₹3,41,55,000
    Reported On9 Jun 2022
    ModeConversion of security
    Vimla BankdaPromoter Group
    Acquired
    40047000
    Shares Worth
    ₹10,13,18,910
    Reported On9 Jun 2022
    ModeConversion of security
    Kedarmal Shankarlal BankdaPromoter
    Acquired
    24000000
    Shares Worth
    ₹6,07,20,000
    Reported On9 Jun 2022
    ModeConversion of security
    Asha Vijay BankdaPromoter Group
    Acquired
    32500000
    Shares Worth
    ₹8,22,25,000
    Reported On28 Feb 2022
    ModeConversion of security